• Genome&Company received conversion requests for 1,446,248 convertible preferred shares into 1,446,248 common shares on Oct. 7, 2026.
• Common shares outstanding to rise to 53,747,673 from 52,301,425; preferred shares to fall to 1,396,947 from 2,843,195.
• Paid-in capital for common shares to increase to KRW 26.87 billion from KRW 26.15 billion.
• Listing of the newly issued common shares scheduled for Oct. 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genome&Company published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007900598), on October 07, 2026, and is solely responsible for the information contained therein.